TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02184637
Drug: Artemether + Lumefantrine
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light yellow, round tablet with NC debossed on one side and CG on the other, containing 20 mg artemether and 120 mg lumefantrine. To be administered orally
Study: NCT02748967
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant will receive single dose of Placebo on Day 1.
Study: NCT04695509
Drug: deep propofol sedation (BIS 60-70, The Richmond Agitation and Sedation scale (RASS) -4)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two peripheral venous blood catheter is placed after admission in the operation room and venous blood sample is taken (10 ml). Complete monitoring of vital functions is provided (pulse oximetry, blood pressure, electrocardiography, bispectral index monitoring). Doctor anesthesiologist performs regional anesthesia and propofol deep sedation starts. The second blood sample (10 ml) is taken 35-40 minutes after the start of propofol sedation. The third blood sample (10 ml) is taken after emergence from propofol sedation (10-15 minutes after propofol discontinuation). Blood samples are centrifuged and received plasma is frozen at a temperature of -20 C\*. After 26 patients are recruited, the blood plasma is analyzed by conducting enzyme-linked immunosorbent assay (ELISA) of neuromediators (Dopamine, serotonin, Gamma-aminobutyric acid (GABA), acetylcholine, noradrenaline).
Study: NCT00914693
Drug: Ethinylestradiol/Gestodene (BAY86-5016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen
Study: NCT04523740
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who use regular paracetamol will now receive 6 to 8 tablets of placebo per day for 2 weeks
Study: NCT02536248
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 6 weeks
Study: NCT00372892
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline IV placebo once per week for 4 consecutive weeks
Study: NCT02413203
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blood and urine collections before and 3 hours after celecoxib administration.
Study: NCT02413203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood and urine collections before and 3 hours after placebo administration.
Study: NCT00570245
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: inhalation, 10 ppm, for up to 48 hours
Study: NCT00570245
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: inhalation; 10ppm; 3 hours (donor) up to 48 hours (recipient)
Study: NCT00884832
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.
Study: NCT02337725
Drug: TVP-1012
Approvals — FDA: no, EMA: no, PMDA: no
Description: TVP-1012 1mg Tablets
Study: NCT02337725
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets
Study: NCT02043886
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non active substance matched to look like Acarbose 50 mg tablets. Taken by mouth during Meal Test.
Study: NCT01642212
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02531815
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for PF-06741086, single dose
Study: NCT00981526
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (plus existing clozapine or olanzapine treatment) for 12 weeks.
Study: NCT04370379
Drug: IBI302 (the first dose level)
Normalized name: The New Parent First Aid KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: q4week (3 injections) followed by PRN dosing
Study: NCT00831376
Drug: racemic salbutamol
Normalized name: EPINEPHRINE,RACEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be asked to take two puffs four times a day for 2 weeks
Study: NCT00831376
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be asked to take two puffs four times a day for 2 weeks
Study: NCT01206907
Drug: oxymorphone IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxymorphone IR liquid
Study: NCT02229773
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02229773
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02229773
Drug: BIBB 1464 MS high dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01931046
Drug: Ad5-SGE-REIC/Dkk3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad5-SGE-REIC/Dkk-3, was designed to increase intracellular production REIC protein. The adenovirus vector is a transport mechanism to infuse the REIC protein into the cell providing a temporary transfusion of protein that induces apoptosis in target cancer cells, but does not appear to have a significant effect on normal tissues.
Study: NCT01228747
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching oral placebo tablets twice daily for 28 weeks
Study: NCT00867750
Drug: Transarterial Chemoembolisation
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACE with embolising agent Embospheres (150-300 μm or 300-500 μm diameter) with 50 mg of chemotherapeutic agent epirubicin admixed with 5 ml lipiodol.
Study: NCT03569267
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01073007
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 40 mgrs daily for three months.
Study: NCT00670787
Drug: Combination pill of losartan and hydrochlorothiazide
Normalized name: hydrochlorothiazide / losartan Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination pill of losartan potassium 50mg and hydrochlorothiazide 12.5mg in the morning
Study: NCT02293863
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single IV dose of placebo matched to MHAA4549A on Day 1
Study: NCT02342639
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill
Study: NCT04083755
Drug: Ferric Carboxymaltose Injection [Injectafer]
Normalized name: ferric carboxymaltose Injection [Injectafer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg intravenous
Study: NCT00083161
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 25 mg by mouth BID days 8-19 or each cycle x 4 cycles. After restaging (if no progression) maintenance cyclophosphamide alone 25 mg by mouth BID daily until disease progression
Study: NCT00805415
Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658K)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 2 and 3 mg
Study: NCT00805415
Drug: EV/DNG (SH T00658L)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 3 and 4 mg
Study: NCT02097680
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo capsule every two days during four months
Study: NCT03055026
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT01485744
Drug: LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDE225 200-800 mg daily orally. Fluorouracil 2400 mg IV every other week. Irinotecan 180 mg/m2 IV every other week. Oxaliplatin 85 mg/m2 IV every other week. Leucovorin 400 mg/m2 IV every other week.
Study: NCT00002462
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01725139
Drug: GSK2126458
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2126458 will be available as film coated tablet of dose strength 0.25 mg and 0.5 mg
Study: NCT01725139
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be available
Study: NCT00477633
Drug: Norethindrone/ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet per day
Study: NCT04776850
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02684071
Drug: Intra thecal methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IT methotrexate via Ommaya reservoir with concomitant systemic topotecan and cyclophosphamide
Study: NCT02684071
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: To be administered in conjunction with methotrexate and topotecan
Study: NCT04479553
Drug: Qizhi Tongluo Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qizhi Tongluo Capsule, a Chinese patent medicine composed of 26 Chinese herbs, has been approved by China Food and Drug Administration for treating recovery period of ischemic stroke (drug approval numbers: B20171001).
Study: NCT01906749
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02063529
Drug: FOLFOXIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
Study: NCT02418130
Drug: Ursodeoxycholic acid, taurine, ginsenoside, thiamine, inositol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02418130
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03539432
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcrystalline cellulose powder packaged in capsules identical to the experimental medication
Study: NCT00318292
Drug: bupivacaine and epinephrine
Normalized name: Bupivacaine and epinephrine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of 0.5% bupivacaine with 1:200,000 epinephrine paracervical injection.
Study: NCT00486902
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 20 mL IV infusion delivered over 10 minutes via an infusion pump set at 2ml/minute
Study: NCT01355289
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03156036
Drug: Capecitabine plus temozolomide VS Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For each cohort of MGMT hypermethylated versus MGMT unmethylated, patients will be randomised (ratio 1:1 for each arm) into preoperative CRT with capecitabine or preoperative CRT with temozolomide plus capecitabine arms.~Chemotherapy during preoperative chemoradiotherapy:~Capecitabine and temozolomide will be administered during radiotherapy with drug holidays (weekend break).~dosage: Capecitabine 825 mg/m2 twice daily, Temozolomide 75 mg/m2/day
Study: NCT02978222
Drug: Adjuvant (GM-CSF) Alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection 125 μg GM-CSF
Study: NCT04727671
Drug: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage adjustment according to the ovarian response.
Study: NCT00541983
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in six successive dose groups will receive a single IV infusion (mg/kg) of study drug on Day 0. The total time of the infusion will be 1 hour ± 15 minutes.
Study: NCT00470496
Drug: photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo laser light exposure
Study: NCT02000609
Drug: CHF 1535 NEXThaler 800/48
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02000609
Drug: CHF 1535 NEXThaler 200/12
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02000609
Drug: CHF 1535 NEXThaler PLACEBO
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02000609
Drug: CHF 1535 pMDI 200/12
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02000609
Drug: CHF1535 pMDI 800/48
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00864240
Drug: Clobex TM (Clobetasol) 0.05% Lotion, single exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received Galderma Laboratories, L.P. formulated products
Study: NCT01912755
Drug: 4% articaine with 1:100,000 epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: If the primary anesthesia failed after ten minutes, an intraligamentary injection with 4% articaine with 1:100,000 epinephrine was performed and the procedure initiated. When access to the pulp chamber was available, intrapulpal anesthesia was given using 4% articaine with 1:100,000 epinephrine.
Study: NCT00619957
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: one placebo once a week for two years followed by one 35 mg risedronate once a week for two years
Study: NCT01508455
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04417257
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally once-a-day with the main meal of the day, if possible, for a total of up to 14 days.
Study: NCT04453111
Drug: Hyalgan 20 mg in 2 ML Prefilled Syringe
Normalized name: Hyalgan 20 MG in 2 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyaluronic Acid 20 mg
Study: NCT02604004
Drug: Epivir ® tablet 150-mg single dose (drug reference)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioequivalence lamivudine 150 mg tablets fasting condition
Study: NCT00535340
Drug: SR58611A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02290210
Drug: URC102 0.25mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02290210
Drug: URC102 0.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02290210
Drug: URC102 1.0mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02290210
Drug: URC102 2.0mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02290210
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02249052
Drug: AA4500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects must present with 2 lipomas; one to receive AA4500 and one to receive placebo simultaneously
Study: NCT02249052
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00138086
Drug: Zevalin plus BEAM
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00665119
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.05 mcg.kg-1.min-1 for 30 minutes by continuous endovenous infusion
Study: NCT00665119
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9 %
Study: NCT01923181
Drug: oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily oral administration as tablets.
Study: NCT02654938
Drug: Mobilan (M-VM3)
Normalized name: M
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobilan (M-VM3), innovative experimental drug based on non-replicate adenoviral delivery system consisting genomic vector coding TLR5-receptor and its ligand 502s.
Study: NCT01575613
Drug: Artemether-lumefantrine combination
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal screening and treatment in all households in malaria hotspots prior to the peak transmission season. Screening of a sentinel age group by rapid diagnostic tests; all parasitaemic individuals and household members of parasitaemic individuals will be treated.
Study: NCT02654938
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% infusion solution of dextrose
Study: NCT01253603
Drug: QAW039 capsules once daily for 28 days
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01253603
Drug: Placebo to QAW039 capsules once daily for 28 days
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00749190
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00710385
Drug: Low Bup/Nal Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/Naloxone 4/1 mg, 8/2 mg
Study: NCT00710385
Drug: High Bup/Nal Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/Naloxone 8/2 mg, 16/4 mg
Study: NCT00710385
Drug: Placebo (PCB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control administration
Study: NCT02839694
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg orally twice a day every day for while on DAC-THU therapy
Study: NCT01455220
Drug: Tysabri ® (Natalizumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV, monthly
Study: NCT01175395
Drug: IBI-20089/Lucentis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combining a single dose of IBI-20089 (6.9 mg or 13.8 mg) intravitreal injection adjunctively with Lucentis 0.5 mg intravitreal injection at baseline and monthly intravitreal Lucentis injection PRN based on clinical and OCT results.
Study: NCT02142036
Drug: EMA-approved ATI based targeted therapy
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: All drugs that may be used in the study are approved by EMA for treatment of disseminated cancer in the palliative setting, but not for the particular tumor type in question.
Study: NCT00633984
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the third, fourth, fifth, sixth, and seventh sessions of the twelve-session program of Cognitive Behavioral Therapy, the patient will be asked to arrive one hour early to take one of the study pill, a placebo. A physician will be available in the unlikely event that a patient begins to experience side effects. Before the treatment starts, before the eighth session, and one week after the final session patients will have a separate visit in which their levels of symptoms assessed with measures of mood, anxiety, and avoidance.
Study: NCT00716716
Drug: rFIXFc
Normalized name: rFIXFc
Approvals — FDA: no, EMA: no, PMDA: no
Description: As specified in the treatment arm
Study: NCT02272790
Drug: PLD
Normalized name: PLD1
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD (pegylated liposomal doxorubicin) 40 mg/m² IV will be given on Day 1 of each 28-Day cycle.
Study: NCT00332202
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, daily
Study: NCT00702143
Drug: florbetapir F 18
Normalized name: Florbetapir F 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV injection, 370MBq (10mCi), single dose
Study: NCT04439890
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03871491
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The study intervention is a single 2 g dose of directly observed oral azithromycin, to be administered as four 500 mg pills or tablets directly after randomization. By random allocation, participants will receive 2 g of oral azithromycin.
Study: NCT03871491
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical appearing placebo, administered as a single oral dose directly after randomization.
Study: NCT02920125
Drug: SUVED
Normalized name: Suvedolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayurvedic formulation in ghana (concentrated) in capsules; 500 mg each
Study: NCT02429999
Drug: Letrezole plus FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: letrozole, 10 mg daily from day 3-7 and FSH 75IU/day from day 5 continuously and GnRH antagonist (orgalutran 0.25) is given when the follicle size equal to 14 mm till hCG injection.
Study: NCT02429999
Drug: Standard protocol for induction of ovulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 decapeptyl from day 21 in the previous cycle and continuously stimulated by FSH (150-225IU/day) from day 2.
Study: NCT01822561
Drug: Eplerenone 50mg
Normalized name: EPLERENONE 50MG TAB
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will receive the same dose of eplerenone.
Study: NCT03050164
Drug: Iressa® Tablet 250mg of AZN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Iressa® Tablet 250mg of AZN was administered after a 10-hour overnight fast.
Study: NCT02113293
Drug: CyclASol®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A Solution
Study: NCT02113293
Drug: Placebo (vehicle)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Solution
Study: NCT02078349
Drug: KPT-330
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each dose will consist of KPT-330 (Selinexor) for oral administration on an mg/m2 basis, and should be based on the patient's actual calculated body surface area (BSA) at baseline. Patients with a BSA \>2.5 m(2) will receive a dose based upon a 2.5 m(2) BSA.
Study: NCT03945279
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT03597464
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voclosporin placebo, oral, 3 capsules twice daily (BID)
Study: NCT03192579
Drug: EPA and high dose rosuvastatin
Normalized name: rosuvastatin and ezetimibe
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After randomization, patients with intensive lipid lowering therapy start EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for 12 months.
Study: NCT00120003
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg on day 1; 8 mg on day 2; 16 mg on days 3-7
Study: NCT03058744
Drug: IDP-118 Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotion
Study: NCT03058744
Drug: HP Monad Lotion
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotion
Study: NCT00609622
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX will be administered every 2 weeks, using the modified FOLFOX6 (mFOLFOX6) regimen, consisting of: - oxaliplatin 85 mg/ m\^2 + leucovorin 400 mg/ m\^2 (or 200 mg/ m\^2 levo-leucovorin) as a 2-hr IV infusion followed by 5-fluorouracil 400 mg/ m\^2 IV bolus on day 1 and 5-fluorouracil 2400 mg/ m\^2 IV infusion over 46 hours on Days 1 and 2 of each 2 week cycle
Study: NCT04743050
Drug: Fatty Acids, Unsaturated
Normalized name: fatty acids, unsaturated
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants from Experimental Groups will receive supplementation of different fractions of EFAs esters for six months daily. Control Group will be monitored with the same tests, but will not receive any supplementation.